BPC-157: Pharmacokinetics, Safety, and Potential for Tissue Regeneration

Source: Chang L. et al., Frontiers in Pharmacology, 2022, 10.3389/fphar.2022.1026182


Study Objective

To determine the pharmacokinetics, distribution, metabolism, and excretion of the peptide BPC-157 (Body Protection Compound-157) in various animal models, and to evaluate its safety and bioavailability via different routes of administration.

BPC-157 is a gastrointestinal peptide that demonstrates strong potential for tissue repair, angiogenesis, and anti-inflammatory effects in preclinical models. This study aims to provide objective pharmacokinetic safety data.


Study Design

  • Type: experimental preclinical study

  • Models: rats (Sprague-Dawley) and dogs (Beagle)

  • Doses and administration:

    • IV (intravenous): 0.4 mg/kg

    • IM (intramuscular): 0.4 mg/kg

    • PO (oral): 0.4 mg/kg

  • Duration: up to 24 hours post-administration

  • Parameters measured:

    • Plasma concentrations of BPC-157

    • Tissue distribution (liver, kidneys, muscles, stomach)

    • Metabolites and elimination pathways

    • Bioavailability (IM, PO vs. IV)


Key Results

Pharmacokinetics and distribution

  • The elimination half-life was approximately 25–30 minutes after IV administration.

  • After intramuscular administration, bioavailability was 45–51% (dogs) and 14–19% (rats).

  • Peak concentrations were reached in 5–15 minutes (IV) and 30–60 minutes (IM).

  • BPC-157 is primarily distributed in the liver, kidneys, muscles, and stomach.

Metabolism and elimination

  • Metabolized into shorter peptides and amino acids by plasma peptidases.

  • Excretion occurs via urine and bile.

Safety

  • No toxic effects or changes in biochemical parameters were observed.

  • Good local tolerance with IM and PO administration.


Conclusions

  • BPC-157 has a short half-life but good tissue penetration and a safe profile.

  • Shows potential for systemic administration via IM and PO routes.

  • Does not cause toxicity or accumulation at single doses.

  • Supports further clinical research for regeneration and recovery.

Limitations

  • Only preclinical animal models (no human data).

  • Short duration (24 hours) – does not assess chronic use.

  • Efficacy not investigated – only pharmacokinetics and safety.

Practical implications

  • BPC-157 is safe in animals at therapeutic doses.

  • Suitable for studies on tissue regeneration, recovery after injuries, and inflammation.

  • Further human studies are needed to determine doses and efficacy.